The complement system in schizophrenia

Karine R. Mayilyan, Daniel Weinberger, Robert B. Sim

Research output: Contribution to journalArticle

Abstract

Several lines of evidence suggest that immunological factors contribute to schizophrenia. Since 1989, the role of complement, a major effector of innate immunity and an adjuvant of adaptive immunity, has been explored in schizophrenia. Increased activity of C1, C3, C4 complement components in schizophrenia has been reported by two or more groups. Two studies on different subject cohorts showed increased MBL-MASP-2 activity in patients versus controls. More then one report indicated a significant high frequency of FB*F allotype and low prevalence of the FS phenotype of complement factor B in schizophrenia. From the data reported, it is likely that the disorder is accompanied by alterations of the complement classical and lectin pathways, which undergo dynamic changes, depending on the illness course and the state of neuro-immune crosstalk. Recent findings, implicating complement in neurogenesis, synapse remodeling and pruning during brain development, suggest a reexamination of the potential role of complement in neurodevelopmental processes contributing to schizophrenia susceptibility. It is plausible that the multicomponent complement system has more than one dimensional association with schizophrenia susceptibility, pathopsychology and illness course, understanding of which will bring a new perspective for possible immunomodulation and immunocorrection of the disease.

Original languageEnglish (US)
Pages (from-to)200-210
Number of pages11
JournalDrug News and Perspectives
Volume21
Issue number4
DOIs
StatePublished - May 2008
Externally publishedYes

Fingerprint

Schizophrenia
Mannose-Binding Protein-Associated Serine Proteases
Mannose-Binding Lectin Complement Pathway
Classical Complement Pathway
Complement C4
Complement Factor B
Immunomodulation
Neurogenesis
Immunologic Factors
Adaptive Immunity
Innate Immunity
Synapses
Phenotype
Brain

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

The complement system in schizophrenia. / Mayilyan, Karine R.; Weinberger, Daniel; Sim, Robert B.

In: Drug News and Perspectives, Vol. 21, No. 4, 05.2008, p. 200-210.

Research output: Contribution to journalArticle

Mayilyan, Karine R. ; Weinberger, Daniel ; Sim, Robert B. / The complement system in schizophrenia. In: Drug News and Perspectives. 2008 ; Vol. 21, No. 4. pp. 200-210.
@article{65b78904df624bb08d13af5ef223a006,
title = "The complement system in schizophrenia",
abstract = "Several lines of evidence suggest that immunological factors contribute to schizophrenia. Since 1989, the role of complement, a major effector of innate immunity and an adjuvant of adaptive immunity, has been explored in schizophrenia. Increased activity of C1, C3, C4 complement components in schizophrenia has been reported by two or more groups. Two studies on different subject cohorts showed increased MBL-MASP-2 activity in patients versus controls. More then one report indicated a significant high frequency of FB*F allotype and low prevalence of the FS phenotype of complement factor B in schizophrenia. From the data reported, it is likely that the disorder is accompanied by alterations of the complement classical and lectin pathways, which undergo dynamic changes, depending on the illness course and the state of neuro-immune crosstalk. Recent findings, implicating complement in neurogenesis, synapse remodeling and pruning during brain development, suggest a reexamination of the potential role of complement in neurodevelopmental processes contributing to schizophrenia susceptibility. It is plausible that the multicomponent complement system has more than one dimensional association with schizophrenia susceptibility, pathopsychology and illness course, understanding of which will bring a new perspective for possible immunomodulation and immunocorrection of the disease.",
author = "Mayilyan, {Karine R.} and Daniel Weinberger and Sim, {Robert B.}",
year = "2008",
month = "5",
doi = "10.1358/dnp.2008.21.4.1213349",
language = "English (US)",
volume = "21",
pages = "200--210",
journal = "Drug News and Perspectives",
issn = "0214-0934",
publisher = "Prous Science",
number = "4",

}

TY - JOUR

T1 - The complement system in schizophrenia

AU - Mayilyan, Karine R.

AU - Weinberger, Daniel

AU - Sim, Robert B.

PY - 2008/5

Y1 - 2008/5

N2 - Several lines of evidence suggest that immunological factors contribute to schizophrenia. Since 1989, the role of complement, a major effector of innate immunity and an adjuvant of adaptive immunity, has been explored in schizophrenia. Increased activity of C1, C3, C4 complement components in schizophrenia has been reported by two or more groups. Two studies on different subject cohorts showed increased MBL-MASP-2 activity in patients versus controls. More then one report indicated a significant high frequency of FB*F allotype and low prevalence of the FS phenotype of complement factor B in schizophrenia. From the data reported, it is likely that the disorder is accompanied by alterations of the complement classical and lectin pathways, which undergo dynamic changes, depending on the illness course and the state of neuro-immune crosstalk. Recent findings, implicating complement in neurogenesis, synapse remodeling and pruning during brain development, suggest a reexamination of the potential role of complement in neurodevelopmental processes contributing to schizophrenia susceptibility. It is plausible that the multicomponent complement system has more than one dimensional association with schizophrenia susceptibility, pathopsychology and illness course, understanding of which will bring a new perspective for possible immunomodulation and immunocorrection of the disease.

AB - Several lines of evidence suggest that immunological factors contribute to schizophrenia. Since 1989, the role of complement, a major effector of innate immunity and an adjuvant of adaptive immunity, has been explored in schizophrenia. Increased activity of C1, C3, C4 complement components in schizophrenia has been reported by two or more groups. Two studies on different subject cohorts showed increased MBL-MASP-2 activity in patients versus controls. More then one report indicated a significant high frequency of FB*F allotype and low prevalence of the FS phenotype of complement factor B in schizophrenia. From the data reported, it is likely that the disorder is accompanied by alterations of the complement classical and lectin pathways, which undergo dynamic changes, depending on the illness course and the state of neuro-immune crosstalk. Recent findings, implicating complement in neurogenesis, synapse remodeling and pruning during brain development, suggest a reexamination of the potential role of complement in neurodevelopmental processes contributing to schizophrenia susceptibility. It is plausible that the multicomponent complement system has more than one dimensional association with schizophrenia susceptibility, pathopsychology and illness course, understanding of which will bring a new perspective for possible immunomodulation and immunocorrection of the disease.

UR - http://www.scopus.com/inward/record.url?scp=51349111299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349111299&partnerID=8YFLogxK

U2 - 10.1358/dnp.2008.21.4.1213349

DO - 10.1358/dnp.2008.21.4.1213349

M3 - Article

C2 - 18560619

AN - SCOPUS:51349111299

VL - 21

SP - 200

EP - 210

JO - Drug News and Perspectives

JF - Drug News and Perspectives

SN - 0214-0934

IS - 4

ER -